← Back to all trials
Enrolling By Invitation
NCT05656599
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Conditions: CMV Infection, Hematopoietic Stem Cell Transplantation
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Enrollment: 120
Sponsor: Peking University People's Hospital
Location: China
Summary
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified.
Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection.Investigators will dynamically monitor the CMV-specific cellular immune reconstitution after HSCT，and analyze the clinical factors and therapy strategies affecting recovery of CMV-specific immunity during 1 year after HSCT.
Eligibility Criteria
Inclusion Criteria:Be receiving a first allogeneic HSCT.Is male or female, from 18 years to any years of age inclusive.The participant (or legally acceptable representative) agree for cellular immune investigation and has provided documented informed consent/assent for the study.Exclusion Criteria:Received a previous allogeneic HSCT (Note: Receipt of a previous autologous HSCT is acceptable).Has a history of CMV end-organ disease within 6 months prior to allocation.Has severe organ (hepatic , renal, cardical) insufficiency within 5 days prior to allocation.Any rapidly-progressing disease or immediately life-threatening illness.
Source: ClinicalTrials.gov (NCT05656599). StuddyBuddy aggregates publicly available trial information.
